DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension.
Yi YanYang-Yang HeXin JiangYong WangJi-Wang ChenJun-Han ZhaoJue YeTian-Yu LianXu ZhangRu-Jiao ZhangDan LuShan-Shan GuoXi-Qi XuKai SunSu-Qi LiLian-Feng ZhangXue ZhangShu-Yang ZhangZhi-Cheng JingPublished in: Science advances (2020)
DNA methylation plays critical roles in vascular pathology of pulmonary hypertension (PH). The underlying mechanism, however, remains undetermined. Here, we demonstrate that global DNA methylation was elevated in the lungs of PH rat models after monocrotaline administration or hypobaric hypoxia exposure. We showed that DNA methyltransferase 3B (DNMT3B) was up-regulated in both PH patients and rodent models. Furthermore, Dnmt3b -/- rats exhibited more severe pulmonary vascular remodeling. Consistently, inhibition of DNMT3B promoted proliferation/migration of pulmonary artery smooth muscle cells (PASMCs) in response to platelet-derived growth factor-BB (PDGF-BB). In contrast, overexpressing DNMT3B in PASMCs attenuated PDGF-BB-induced proliferation/migration and ameliorated hypoxia-mediated PH and right ventricular hypertrophy in mice. We also showed that DNMT3B transcriptionally regulated inflammatory pathways. Our results reveal that DNMT3B is a previously undefined mediator in the pathogenesis of PH, which couples epigenetic regulations with vascular remodeling and represents a therapeutic target to tackle PH.
Keyphrases
- dna methylation
- pulmonary hypertension
- pulmonary artery
- growth factor
- genome wide
- pulmonary arterial hypertension
- gene expression
- end stage renal disease
- oxidative stress
- endothelial cells
- coronary artery
- signaling pathway
- chronic kidney disease
- magnetic resonance
- single molecule
- newly diagnosed
- transcription factor
- smooth muscle
- circulating tumor
- skeletal muscle
- early onset
- insulin resistance
- computed tomography
- type diabetes
- diabetic rats